Abbott Seeks Approval in US, Japan for Dx to Pick Best Responders to Pfizer's Crizotinib

Shortly after Pfizer's regulatory filings for the NSCLC ALK-inhibitor crizotinib in these two countries, Abbott submitted its premarket approval application with US and Japanese regulatory authorities for a FISH-based companion diagnostic test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.